NCT03650764View on ClinicalTrials.gov

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Ramucirumab

Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient

DRUG

Pembrolizumab

Pembrolizumab is commercially available

OTHER

EORTC QLQ-30

-Screening, start of cycle 2, start of cycle 5

OTHER

FACT H&N

-Screening, start of cycle 2, start of cycle 5

PROCEDURE

Peripheral blood

-Baseline

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Washington University School of Medicine

OTHER